SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as the community leans into its status as a foundational internet meme, driven by the restoration of its original meme-making tools and the promotion of its historical cultural relevance. Investors are actively discussing the project's long-term potential, emphasizing community-led efforts and a commitment to 'bagworking' as they position the token within the Solana ecosystem.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy token, associated with the controversial EV stock legacy, is currently generating debate as community members push for renewed momentum and higher market valuations despite significant skepticism from those labeling it a pump-and-dump scam. Investors are actively discussing entry points, sharing contract addresses for Solana-based trading, and comparing the project's volatile history to broader market trends.

Maul Coin

Maul Coin is generating significant community buzz and price volatility as investors push to break through resistance levels and secure a chart listing on tracking platforms. The project is being championed by an active developer and a dedicated base of holders who are heavily promoting the coin across social media to fuel a potential breakout.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is currently trending as investors focus on breakthrough device designations and clinical trial progress for its nsPFA technology. The community is actively discussing potential buyout opportunities and institutional interest, while closely tracking executive leadership changes and upcoming trial milestones.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

Troll is gaining significant market attention as community members rally behind its status as an 'OG' meme coin, frequently drawing parallels to other cult-status assets. The conversation is heavily focused on the coin's historical origins, ongoing meme-centric branding, and widespread belief among proponents that it is positioned for sustained long-term growth alongside other community-driven projects.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The XRP community remains deeply divided, with bulls pointing to ongoing Ripple developments and anticipation of the Clarity Act as long-term catalysts, while bears focus on stagnant price action and frustration over Ripple's token management. Despite the ongoing market volatility, discussion is dominated by debates over institutional adoption, the role of stablecoins on the XRP Ledger, and whether the asset can maintain its relevance in a shifting regulatory landscape.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for community discussion as investors debate its long-term potential versus recent price volatility, with many highlighting its post-quantum security features and institutional moves as catalysts for future growth. While some traders are actively monitoring entry points for accumulation, others are expressing frustration over the project's extended drawdown and shifts in the broader digital asset landscape.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently capturing significant community attention as it navigates market volatility, with active discussions focused on its developer ecosystem, institutional adoption, and recent platform-level hacks that have stirred intense debate among traders. Investors are closely monitoring its performance as a leading altcoin, with sentiment split between long-term bullish outlooks on its infrastructure and cautionary discussions regarding price fluctuations and competitive network dynamics.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

The NEOS Nasdaq 100 High Income ETF (QQQI) is seeing strong community interest as investors actively rotate into high-yield, income-focused funds that aim to pair consistent monthly distributions with capital preservation strategies. Enthusiasts are highlighting its tax-efficient return-of-capital structure and ability to provide yield during sideways market conditions, often debating its long-term performance and tactical role compared to broader Nasdaq-100 benchmarks.

COTI is a fast and light confidentiality layer on Ethereum. Powered by the breakthrough cryptographic protocol Garbled Circuits and secured by Ethereum, COTI introduces the most advanced and compliant solution for data protection on the public blockchain. Paving the way for the next wave of Web3 innovation and adoption, COTI unlocks a whole new world of use cases, including confidential transactions, Artificial Intelligence, DeFi, decentralized identification, and more.

COTI

COTI is gaining significant momentum and attention as the community rallies around its innovative garbled circuits technology and the recent transition to mainnet. Investors are actively discussing the protocol's potential to provide programmable, compliant privacy for real-world assets, with many highlighting its perceived competitive edge and growth potential in the evolving privacy sector.

statis crypto Watchlist

Bitcoin

Ethereum

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investors Purchase High Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Stock traders acquired 9,003 call options on the stock. This...

Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Assenagon Asset Management S.A. trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 88.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 359,580 shares of the biotechnology co...

BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 28.5% during the 3rd quarter, according to its most recent 13F filing with the...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - What's Next?

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - Should You Buy...

<ul class="summary-bullets"><li>Elevated oil prices and Middle East tensions are keeping traders on the edge.</li><li>Investors are eyeing PMI data and GameStop earnings as near-term catalysts for market direction.</li><li>AI stocks remain in focus amid fresh supply chain concerns and geopolitical scrutiny around chip exports.</li></ul>U.S. stock futures rose early Tuesday, attempting to build on the recovery seen in the previous market session. However, investors remain cautious amid the uncertainty in the Middle East. Traders will also be watching for cues from manufacturing data due this morning and Gamestop earnings later today.&nbsp;Crude oil prices rose on concerns that the Iran conflict could reportedly expand to U.S. allies in the Persian Gulf. This comes even as Iranian lawmakers dismissed the possibility of negotiations with the U.S. As of 4:30 a.m. ET on Tuesday, Dow and S&amp;P 500 futures rose 0.2%, and Nasdaq and Russell 2000 futures were up 0.3%.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘extremely bearish, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has remained ‘bearish’ amid high trading volume.&nbsp;Trending Stocks To Watch Nvidia (NVDA):&nbsp;Following the SMCI crisis, U.S. Senators are reportedly demanding a suspension of the AI bellwether’s GPU export licenses to China and Southeast Asia.&nbsp;Broadcom (AVGO):&nbsp;The chipmaker has reportedly warned that its manufacturing partner, TSMC, is nearing capacity for the year, adding to supply concerns.&nbsp;Oracle (ORCL) and Alibaba (BABA):&nbsp;Reports suggest they have launched significant “agentic AI” initiatives.&nbsp;Alibaba has unveiled a new chip design, while Oracle is said to be embedding AI agents in its cloud-based financial software.&nbsp;Amazon (AMZN):&nbsp;The company has said its Bahrain AWS region has been disrupted by drone activity in the Middle East.&nbsp;Gamestop (GME):&nbsp;The video game retailer reports earnings after the bell today. Investors will be tracking any updates on its Bitcoin treasury or an AI-driven pivot.BioCryst Pharmaceuticals (BCRX): The stock is garnering heavy retail attention following takeover speculation.Applied Optoelectronics (AAOI):&nbsp;The stock was trending on Stocktwits following confirmation of a $53 million order for its 800G data center transceivers.&nbsp;Vertiv Holdings Co. (VRT): The stock is on retail radar after it agreed to acquire Italy-based ThermoKey.&nbsp;And&nbsp;Estee Lauder&nbsp;(EL)&nbsp;is reportedly exploring a merger with Puig. Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Intuitive Machines (LUNR), Micron Technologies (MU), Fastly Inc (FSLY), and The Metals Company (TMC).&nbsp;Other Catalysts To WatchOn the economic front, investors will be tracking the S&amp;P Global Manufacturing &amp; Services PMI at 9:45 am ET. Also, watch out for commentary from&nbsp;Fed Vice Chair for Supervision&nbsp;Michael Barr‘s speech at 6:30 pm ET.&nbsp;On earnings radar, watch out for quarterly reports from&nbsp;Achieve Life Sciences Inc.(ACHV), Greenland Technologies Holding Corp (GTEC), and Huami Corp (ZEPP), before the bell. Meanwhile.&nbsp;Fortress Biotech Inc (FBIO), Durect Corp (DRRX), and Scienture Holdings Inc. (SCNX) are among other companies reporting after market close today.&nbsp; For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Rise Ahead Of PMI Data, Iran Tensions Cap Risk Appetite: Why NVDA, GME, AAOI, BCRX Are Keeping Traders Engaged Today

Data from Stocktwits indicated that retail sentiment has remained bearish on SPY and QQQ for over a week. 

Equity

Data from Stocktwits indicated that retail sentiment has remained bearish on SPY and QQQ for over a week. 


BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen brokerages that are presently covering the stock, MarketBeat...

<ul class="summary-bullets"><li>Retail traders debated the timing and pricing of the buyout, with some expecting an all-cash offer and others speculating about various takeover scenarios.</li><li>Skeptical users noted BioCryst’s history as an acquirer and argued shares would likely trade closer to $14-$15 if firm deal insights existed.</li><li>The company's growth remains anchored by Orladeyo, which generated $601 million in revenue and $214 million in non-GAAP operating profit last year.</li></ul>Shares of BioCryst Pharmaceuticals, Inc. (BCRX) jumped about 11% in after-hours trading on Monday as retail sentiment hit its strongest level of 2026 and volumes doubled, fueling speculation that a U.S. biopharma worth over $15 billion could be circling the company.<a href="https://stocktwits.com/symbol/BCRX">BCRX stock</a> ended over 1% higher at $9.8 on Monday, with shares up 23% over the past year.<h2 class="st-heading-2">Retail Investors Weigh Buyout Odds For BCRX</h2>The renewed takeover buzz followed last week's reports of a Betaville “uncooked” alert, which said that a party interested in BioCryst may be a U.S.-based biopharma firm with a market cap exceeding $15 billion.&nbsp;Among the biotech companies with a market cap between $15 billion and $20 billion are Incyte Corp., Revolution Medicines, Inc., Roivant Sciences Ltd., and Exact Sciences Corp.On Stocktwits, retail sentiment for BCRX has remained ‘extremely bullish’ over the past three months and recently climbed to its strongest level of 2026 amid nearly a 300% surge in message volumes, with investors debating whether the after-hours rally reflected positioning ahead of a potential acquisition.<figure class="image"><img src="https://news.stocktwits-cdn.com/bcrx_ss_png_4999553778.webp" alt="bcrx ss.png" width="967" height="144"><figcaption>BCRX sentiment and message volume as of March 23 | Source: Stocktwits</figcaption></figure>One trader&nbsp;<a href="https://stocktwits.com/SCCT2FL/message/648340880">said</a>, “Somebody knows something. A $10 stock doesn’t just go up 10%+ for nothing after hours.” Meanwhile, another trader&nbsp;<a href="https://stocktwits.com/Iwillbuy/message/648308700">expects</a> a buyout to be announced as soon as Wednesday, in an all-cash offer.Some observers&nbsp;<a href="https://stocktwits.com/tkr/message/648180984">suggested</a> institutional positioning at lower levels supported the takeover narrative, arguing that entry around $9.7 signaled confidence in further upside and the possibility that larger pharmaceutical companies could emerge as bidders.<figure class="image"><img src="https://news.stocktwits-cdn.com/bcrx_sentiment_png_404b898eb7.webp" alt="bcrx sentiment.png" width="973" height="447"><figcaption>BCRX sentiment as of March 23 | Source: Stocktwits</figcaption></figure>Others&nbsp;<a href="https://stocktwits.com/Money_Mane/message/648056955">framed</a> possible price scenarios depending on whether a deal materializes, estimating the shares could reach $16-$18 in a buyout case, trade toward $13-$16 with continued execution, or fall toward $7-$9 if competition increases, with further downside possible if pipeline expectations weaken.&nbsp;However, not all views supported the takeover thesis. One user&nbsp;<a href="https://stocktwits.com/doublebtx/message/648310647">noted</a> that the company’s history suggested it may prefer acting as an acquirer rather than a target, while another argued that if investors had firm takeover insight, the stock would already be trading closer to $14-$15.&nbsp;“If the BO [buyout] speculation (if that even is what is happening) goes away, this certainly could drop back,”&nbsp;<a href="https://stocktwits.com/doublebtx/message/648126797">said</a> one user. “But I would just like to point out that even at these levels, this is not even trading at 4x current revs. So it is certainly not overvalued here with or without BO rumors.”<h2 class="st-heading-2">Orladeyo Anchors Growth Outlook</h2>The takeover speculation surfaced alongside improving pipeline visibility, highlighted earlier this month at the TD Cowen 46th Annual Health Care Conference. CEO Charlie Gayer said the company generated $601 million in revenue last year from Orladeyo, its oral preventive treatment for hereditary angioedema, and $214 million in non-GAAP operating profit.“Orladeyo is still the most differentiated product on the market because it’s the only oral prophylactic on the market today,” Gayer said, adding that half of the patients starting Orladeyo are switching from injectable prophylaxis therapies.The company also highlighted Navenibart, the late-stage hereditary angioedema therapy&nbsp;acquired with Astria, as a key driver of future franchise expansion. It also noted that the composition-of-matter patent protection for Orladeyo extends to 2040.Gayer added that the broader portfolio outlook remains strong: “We’re talking about a portfolio that we see growing at mid-teens in revenue well into the 2030s.”For updates and corrections, email newsroom[at]stocktwits[dot]com.

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

BioCryst Stock Jumps After Hours On Big Pharma Suitor Buzz — Retail Sentiment Hits 2026 Peak

Betaville’s “uncooked” alert from last week flagged potential interest in BioCryst from a U.S.-based biopharma with a market cap above $15 billion.

Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today?

Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 150,000 Shares of Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 150,000 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the completion of the...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $1,372,500.00 in Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 150,000 shares of the company's stock in a transaction dated Monday, March 16th. The shares were sold at an...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 13.8% - Here's What Happened

BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 13.8% - Should You Buy...

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Stocktwits

Stocktwits Polls

Traders are intensely speculating about a potential acquisition despite skepticism and frequent price action volatility.

Large block trades and significant after-hours volume are sparking theories about institutional accumulation and hidden market moves.

Significant call option accumulation, specifically in the $10-$12 strike range, has investors debating a potential upcoming rally.

Technical analysts are closely monitoring retrace zones and patterns to predict the next pivot point in a volatile sequence.

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BCRX News

BCRXBiocryst Pharmaceuticals Inc.